H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab to $49 from $51 and keeps a Buy rating on the shares post the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab to Present at Jefferies London Healthcare Conference
- Major Shareholder Announcement
- Genmab upgraded to Buy from Sell at DNB Markets
- Genmab Announces Financial Results for the First Nine Months of 2023
- Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)